{"id":19050,"date":"2025-06-27T12:33:21","date_gmt":"2025-06-27T12:33:21","guid":{"rendered":"https:\/\/www.europesays.com\/us\/19050\/"},"modified":"2025-06-27T12:33:21","modified_gmt":"2025-06-27T12:33:21","slug":"opus-genetics-ird-receives-reiteration-of-buy-rating-from-hc-w","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/19050\/","title":{"rendered":"Opus Genetics (IRD) Receives Reiteration of Buy Rating from HC W"},"content":{"rendered":"

On June 27, 2025, Opus Genetics (IRD<\/a>, Financial<\/a>) received an updated analyst rating from HC Wainwright & Co., a prominent financial services firm. Analyst Matthew Caufield has reiterated a “Buy” rating for the company, maintaining a positive outlook on its performance.<\/p>\n

The analyst has sustained the price target for Opus Genetics (IRD<\/a>, Financial<\/a>) at $8.00 USD, showing confidence in the stock’s potential value. This target remains unchanged from the prior evaluation, reflecting a consistent view of the company’s prospects in the market.<\/p>\n

It is noteworthy that both the current rating and the price target mirror the previous analysis, indicating a stable and optimistic sentiment towards Opus Genetics (IRD<\/a>, Financial<\/a>) by HC Wainwright & Co. This recommendation suggests that the company continues to be a favorable investment option based on its current and forecasted market conditions.<\/p>\n

Wall Street Analysts Forecast <\/p>\n

\"1938562586517860352.png\"\/<\/p>\n

Based on the one-year price targets offered by 4 analysts, the average target price for Opus Genetics Inc (IRD<\/a>, Financial<\/a>) is $14.75 with a high estimate of $20.00 and a low estimate of $10.00. The average target implies an
\nupside of 1,346.08%
\n from the current price of $1.02. More detailed estimate data can be found on the Opus Genetics Inc (IRD) Forecast page<\/a>.<\/p>\n

Based on the consensus recommendation from 4 brokerage firms, Opus Genetics Inc’s (IRD<\/a>, Financial<\/a>) average brokerage recommendation is currently 2.0, indicating “Outperform” status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.<\/p>\n

Based on GuruFocus estimates, the estimated GF Value<\/a> for Opus Genetics Inc (IRD<\/a>, Financial<\/a>) in one year is $1.31, suggesting a
\n upside
\n of 28.43% from the current price of $1.02. GF Value is GuruFocus’ estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business’ performance. More detailed data can be found on the Opus Genetics Inc (IRD) Summary page<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"On June 27, 2025, Opus Genetics (IRD, Financial) received an updated analyst rating from HC Wainwright & Co.,…\n","protected":false},"author":3,"featured_media":19051,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[347,815,17970,17971,17972,50,159,67,132,68],"class_list":{"0":"post-19050","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-article","9":"tag-genetics","10":"tag-gurufocus","11":"tag-gurufocus-news","12":"tag-ird","13":"tag-news","14":"tag-science","15":"tag-united-states","16":"tag-unitedstates","17":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114755352250407237","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/19050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=19050"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/19050\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/19051"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=19050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=19050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=19050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}